Literature DB >> 20562028

Lympho-geographical concepts in vaccine delivery.

Pål Johansen1, Deepa Mohanan2, Julia M Martínez-Gómez2, Thomas M Kündig2, Bruno Gander3.   

Abstract

The key triggers and regulators of immune responses are antigens and their appearance in immune-privileged secondary lymphatic organs. Currently, the majority of vaccines are administered intramuscularly or subcutaneously, although neither the muscular tissue nor the subcutis is particularly rich in immuno-competent cells. Thus, introducing antigens at sites with a higher density of immune-competent cells, such as the dermis, lymph nodes, or afferent lymphatic conducts, with appropriate formulations and injection devices may induce more efficacious immune responses and protection. In this work, we first reviewed the geographical and functional map of the most important lymphatic elements that play a key role in the induction of a specific immune response, such as site of injection, choice of adjuvants and etc. In a first set of experiments, we demonstrated that short intervals of boosting (daily versus weekly) increase the production of IgG2a antibody against the injected model antigen, while increasing rather than constant booster doses increase the number of antigen-specific CD8(+) IFN-γ producing cells. Such antigen presentation patterns reflect the initially increasing amounts of antigen associated with natural infections by highly virulent and replicating pathogens. In a second set of experiments, we studied the importance of administration route (subcutaneous, intradermal, intramuscular, intralymphatic) for the induction of antigen-specific IgG2a, and of IFN-γ produced by antigen-specific lymphocytes when using PLGA microparticles for delivery of antigen. Interestingly, both IgG2a and IFN-γ production were significantly enhanced after intramuscular and intra-lymph node administration when compared to the other two routes. In conclusion, the results suggest that traditional vaccination schedules and administration routes should be reconsidered in vaccine development, particularly when using more advanced formulations and delivery systems such as micro- and nanoparticles or combinations of antigen and immune-response modifiers.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562028     DOI: 10.1016/j.jconrel.2010.05.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  20 in total

1.  Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

Authors:  C Cubillos-Zapata; E Guzman; A Turner; S C Gilbert; H Prentice; J C Hope; B Charleston
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 2.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

3.  Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.

Authors:  Morteza Abkar; Abbas Sahebghadam Lotfi; Jafar Amani; Khadijeh Eskandari; Mehdi Fasihi Ramandi; Jafar Salimian; Gholamreza Nikbakht Brujeni; Saeed Alamian; Mehdi Kamali; Hamid Koushki
Journal:  Vet Res Commun       Date:  2015-09-22       Impact factor: 2.459

4.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.

Authors:  Sarah N Mueller; Shaomin Tian; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2015-04-08       Impact factor: 4.939

5.  Real-Time Imaging of Vaccine Biodistribution Using Zwitterionic NIR Nanoparticles.

Authors:  Wataru Katagiri; Jeong Heong Lee; Marc-André Tétrault; Homan Kang; Sinyoung Jeong; Conor L Evans; Shinya Yokomizo; Sheena Santos; Catherine Jones; Shuang Hu; Georges El Fakhri; Kosuke Tsukada; Hak Soo Choi; Satoshi Kashiwagi
Journal:  Adv Healthc Mater       Date:  2019-06-05       Impact factor: 9.933

6.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles.

Authors:  Christopher M Jewell; Sandra C Bustamante López; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

7.  Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.

Authors:  Weidong Zhang; Myunggi An; Jingchao Xi; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-07-06       Impact factor: 4.774

Review 8.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 9.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

10.  Intralymphatic immunotherapy and vaccination in mice.

Authors:  Pål Johansen; Thomas M Kündig
Journal:  J Vis Exp       Date:  2014-02-02       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.